key: cord-1027406-m5u0woih
authors: Roussel, M.; Ferrant, J.; Reizine, F.; Le Gallou, S.; Dulong, J.; Carl, S.; Lesouhaitier, M.; Gregoire, M.; Bescher, N.; Verdy, C.; Latour, M.; Bézier, I.; Cornic, M.; Vinit, A.; Monvoisin, C.; Sawitzki, B.; Leonard, S.; Paul, S.; Feuillard, J.; Jeannet, R.; Daix, T.; Tiwari, V. K.; Tadié, J. M.; Cogné, M.; Tarte, K.
title: Comparative immune profiling of acute respiratory distress syndrome patients with or without SARS-CoV2 infection
date: 2021-05-06
journal: Cell Rep Med
DOI: 10.1016/j.xcrm.2021.100291
sha: 574c0d36b377d0fe79c24b0ec8a9b93a334c428a
doc_id: 1027406
cord_uid: m5u0woih

Acute respiratory distress syndrome (ARDS) is the main complication of COVID-19, requiring admission to Intensive Care Unit (ICU). Despite extensive immune profiling of COVID-19 patients, to what extent COVID-19-associated ARDS differs from other causes of ARDS remains unknown. To address this question, we build 3 cohorts of patients categorize in COVID-19negARDSpos, COVID-19posARDSpos, and COVID-19posARDSneg, and compare their immune landscape analyze by high-dimensional mass cytometry on peripheral blood. A cell signature associating S100A9/calprotectin-producing CD169pos monocytes, plasmablasts, and Th1 cells is found in COVID-19posARDSpos, unlike COVID-19negARDSpos patients. Moreover, this signature is essentially share with COVID-19posARDSneg patients, suggesting that severe COVID-19 patients, whatever they experience or not ARDS, display similar immune profiles. We show an increase in CD14posHLA-DRlow and CD14lowCD16pos monocytes correlate to the occurrence of adverse events during ICU stay. We demonstrate that COVID-19-associated ARDS display a specific immune profile, and might benefit from personalize therapy in addition to standard ARDS management.

The SARS-Coronavirus-2 (SARS-CoV-2) virus has rapidly affected more than 30 million people worldwide, requiring admission to Intensive Care Unit (ICU) for more than 2 million patients. 1 Whereas most patients exhibit mild-to-moderate symptoms, acute respiratory distress syndrome (ARDS) is the major complication of the coronavirus disease 2019 (COVID-19), 2,3 leading to prolonged ICU stays, and high frequency of secondary complications, notably cardiovascular events, thrombosis, pulmonary embolisms, and strokes. 1, 4 The immune system plays a dual role in COVID-19, contributing to both virus elimination and ARDS development. 5 Excessive inflammatory response has been proposed as the leading cause of COVID-19-related clinical complications, thus supporting intensive efforts to better understand the specificities and mechanisms of SARS-CoV-2-induced immune dysfunction. 6, 7 Moreover, even if therapies such as provided by convalescent plasma or neutralizing antibodies at an early stage of the disease, can lower the viral burden, this was only demonstrated in specific populations such as aged patients over 75, 8 and no antiviral treatment has yet been able to definitely prevent the evolution of some patients towards deregulated inflammation and critical respiratory complications. The benefit of corticosteroids in severe COVID-19 for lowering overall mortality is now widely acknowledged. 9,10 Conversely, steroid therapy was shown harmful in other ARDS etiologies, such as in influenza-associated ARDS, 11 suggesting specific biological features of COVID 19related ARDS. A detailed understanding of the COVID-19-specific immune dysfunctions underlying ARDS development and severity is thus a major need and will hopefully help adapt specific therapeutic strategy.

A number of high-resolution studies have recently concentrated on the determination of circulating markers that can distinguish severe from mild forms of COVID-19, providing a tremendous amount of data describing phenotypic and functional alterations in T cell, B cell, and J o u r n a l P r e -p r o o f myeloid cell subsets. [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] In particular, CD14 pos HLA-DR low , CD14 pos CD16 pos , and immature monocytes were demonstrated as increased among peripheral blood mononuclear cells (PBMCs) from critically ill COVID-19 patients. 15, 21, 23, [26] [27] [28] [29] Interestingly, monocyte number is reduced in COVID-19 compared to influenza patients, suggesting specific myeloid dysregulation. 30 Various COVID 19-related alterations of lymphoid cells have also been described, including a T-cell lymphopenia, predictive of patient outcome, a broad T-cell activation including Th1, Th2, and Th17, an alteration of B-cell and T-cell repertoires, and a strong increase of plasmablasts, most prominent in ARDS COVID-19 patients. 14, 17, 25, [31] [32] [33] Importantly, COVID-19 ARDS immune profiling was performed using healthy donors as a control, thus precluding any conclusions on whether reported immune alterations could be related to COVID-19 and/or ARDS status.

Answering this question has potential to decipher whether ARDS induced by SARS-CoV-2 is mechanistically different from other ARDS etiologies.

To fill this gap, we performed a high-throughput mass cytometry approach on PBMCs obtained 

Analyses were performed on a cohort 1 of 63 cryopreserved PBMC samples isolated from 42 patients included in ICU (n = 36) or infectious standard ward (n = 6). The demographic J o u r n a l P r e -p r o o f characteristics of patients included are provided in Table 1 and Table S1 . All patients but one were classified as severe at admission, requiring oxygen at a flow rate higher than 2 liters/min. ARDS was defined in accordance with international guidelines. 34 Patients were classified in 3 groups: COVID-19 neg ARDS pos (n = 12, ARDS stages: 1 mild, 4 moderate, 7 severe), COVID-19 pos ARDS pos (n = 13, ARDS stages: 8 moderate, 5 severe), and COVID-19 pos ARDS neg (n = 17, including 11 from ICU and 6 from infectious standard ward). In the COVID-19 pos ARDS neg , no statistical differences were noticed for immune cell abundance or phenotype between ICU and standard ward patients. Within the COVID-19 neg ARDS pos group, ARDS etiologies were bacterial pneumonia (n = 9), anti-synthetase syndrome (n = 1), and unknown (n = 2) (Table S1 ). For 21 patients, a second blood sample obtained on day 7 after enrollment was studied (n = 7 for COVID-19 neg ARDS pos , n = 8 for COVID-19 pos ARDS pos , and n = 6 for COVID-19 pos ARDS neg ).

Additionally, a validation cohort (cohort 2) was set up with 16 patients with demographic data detailed in Table S1 and Table S2 . Patients were classified in 3 groups: COVID-19 neg ARDS pos (n = 6), COVID-19 pos ARDS pos (n = 5), and COVID-19 pos ARDS neg (n = 3); additionally, COVID-19 neg ARDS neg (n = 2) samples were included. None of our patients received corticosteroids at the time of the study nor immune-modulators. The presence of SARS-CoV-2 in respiratory specimens (nasal and pharyngeal swabs or sputum) was detected by real-time reverse transcription polymerase chain reaction (RT-PCR) methods. To rule out undetected infections, negative RT-PCR samples were confirmed when possible by absence of neutralizing antibodies.

Neutralizing antibodies were undetectable for the 11 samples out of 18 COVID-19 neg patients for which material was available. In contrast, neutralizing antibodies were detected in 29 out of 30 COVID-19 pos tested. Timeline of sample collection are shown in Fig. S1 .

To decipher the impact of SARS-CoV2 on circulating immune cells, we characterized PBMCs from COVID-19 pos versus COVID-19 neg patients at admission using two separate mass cytometry panels exploring myeloid and lymphoid subsets, respectively (Table S3 and Key Resources   Table) . The full pipeline of analysis is depicted in Fig. S1 . First, we performed an unbiased discovery approach with CellCnn, a neural network-based artificial intelligence algorithm allowing analysis of single-cell data and detection of cells associated with clinical status. [35] [36] [37] During training, CellCnn learns combinations of weights for each marker in a given panel that best discriminate between groups of patients. These weight combinations, called filters, can be used to highlight the specific profiles of cells associated with patient status. We identified the best-performing CellCnn filters for both the myeloid and the lymphoid panels highlighting a population of cells significantly enriched in COVID-19 pos patients as compared to COVID-19 neg patients (P < 0.0001 for both panels) (Fig. 1A ). Projecting these cells on tSNE maps generated with either the myeloid or the lymphoid panels revealed that they fell into several distinct areas (Fig. 1B) . The cells selected by the CellCnn filter on the myeloid panel showed high expression for CD169, CD64, S100A9, CD11b, CD33, CD14, and CD36 compared to background, while the cells selected by the CellCnn filter on the lymphoid panel showed high expression for CD38 and CXCR3 ( Fig.1B and Fig. S2 ). These results were replicated in the cohort 2 ( Fig. S3) , and confirmed on a public set of data by using the CellCnn analysis showing a high expression of CD14, CD36, CD64, and CD169 cells on COVID-19 pos patients (Fig. S4 ). 15 As a whole, this broad and unbiased approach reproducibly showed that immune markers, in particular related to monocytes, segregated COVID-19 neg and COVID-19 pos patients.

J o u r n a l P r e -p r o o f To investigate circulating monocyte heterogeneity and define consistent phenotypes, we used the FlowSOM algorithm. This approach led to the identification of 15 monocyte metaclusters from the myeloid panel ( Fig. 2A) . In particular, Mo30, Mo11, and Mo28 metaclusters were defined by higher expression of CD16 and lower expression of CD14, CD36, and CD64, corresponding to a non-classical monocyte phenotype. Mo21 and Mo22 were defined by the high expression of S100A9 and the low expression of CD36. Finally, Mo243 and Mo180 strongly expressed S100A9, CD169, and CD36. To assess the phenotypic changes in monocytes during SARS-CoV2 infection, we determined the frequencies of these metaclusters in each patient at admission and performed hierarchical clustering on these values (Fig. 2B) . The upper branch of the hierarchical clustering included 20 COVID pos (10 ARDS neg and 10 ARDS pos ) and 1 COVID neg ARDS pos patient whereas the lower branch included 10 COVID pos (7 ARDS neg and 3 ARDS pos ) and 11 COVID neg ARDS pos (chi-square = 0.001) (Fig. 2B) . We then analyzed the abundance of individual metaclusters and identified only 4 metaclusters out of 15 as differentially represented between the 3 groups of patients ( Fig. 2C and Fig. S2 ). In particular, within ARDS pos patients, Mo11 and M181 were less abundant in COVID-19 pos patients (P < 0.01 and P < 0.05, respectively), while Mo243 and Mo180 were more abundant (P < 0.05 and P < 0.001) (Fig. 2C ). No differences were detected within COVID-19 pos groups (ARDS pos versus ARDS neg ) (Fig. 2C) . Interestingly, Mo243 and Mo180 were both enriched in cells highly expressing CD169, CD64, CD36, and CD14 ( Fig.   2A and 2D). Additionally, Mo22 was present only in some COVID pos patients and also expressed CD169 (Fig. 2B) . Taken together, Mo243, Mo180, and Mo22 metaclusters were highly enriched in COVID-19 pos patients when compared to COVID-19 neg patients (P < 0.0001), with no difference regarding the ARDS status (Fig. 2E) . Accordingly, CD169 was differentially expressed in COVID-19 pos versus COVID-19 neg patients (P < 0.001) (Fig. 2E) . Altogether, our study including COVID-19 and non-COVID-19 critically ill patients suggest a specificity of J o u r n a l P r e -p r o o f CD169 expression in COVID-19 patients, and greatly extend previous scRNAseq data showing an expansion of CD169-expressing monocytes in COVID-19 patients compared to healthy donors ( Fig. 2F) . 15, 25, [38] [39] [40] We then performed the FlowSOM analysis on cohort 2 and validated the enrichment of Mo243 and Mo180 in COVID-19 pos samples (Fig. S3A, S3B ), these metaclusters also presenting a trend for high CD169 expression (Fig. S3C ).

To define a more global immune pattern and the relationship between immune cells in the context of the SARS-CoV2 infection, we sought for correlation between frequencies of clusters of T-, NK-, B-, and plasma cells (n = 136 clusters from the lymphoid panel, Fig. S1 ) and the 4 monocyte metaclusters (Mo11, Mo181, Mo243, and Mo180) previously described. This analysis identified 70 clusters with significantly correlated variations (P < 0.05) (Fig. S2 ). To strengthen the relevance of these correlations, we restrained further analysis to the 29 strongest relationships (R > 0.5 or < -0.5 and P < 0.01) between Mo180 or Mo243 (the two metaclusters enriched in COVID-19 patients) and other immune cell subsets ( Fig. 3A and Table S4 ). As expected, Mo180 and Mo243 metaclusters were correlated (R = 0.93). Moreover, they were positively correlated with 18 clusters of T (n = 6), NK (n = 10), and plasma cells (n = 2), and inversely correlated with 11 clusters of T (n = 9), and NK cells (n = 2) (Fig. 3A) . Among positively correlated clusters, plasmo_183 and plasmo_198 similarly expressed CD38, CD44, and CD27, whereas plasmo_183 was high for Ki-67 and HLA-DR, corresponding to an early plasma cell phenotype (Fig. 3B) . NK cells were all marked by CD7 and T-bet expression, NK_209 being CD8 high , and NK_241 and NK_197 displaying a Ki-67 high proliferating phenotype. The related T8_147 and T8_161 clusters exhibited a CD45RA high CD45RO low CCD7 low CD27 low Tbet high CD38 high effector phenotype. Few J o u r n a l P r e -p r o o f T4 clusters were positively correlated with Mo180 and Mo243, among them T4_106 displayed an effector memory proliferating phenotype (Ki-67 high CD45RA low CCR7 low CD45RO high CD27 high and CTLA4 high PD1 high ). T4_25 was also marked by an effector memory phenotype (CD45RA low CCR7 low CD45RO pos ) and displayed a CD27 low CD127 pos CCR6 pos CxCR3 neg CD161 pos Th17 profile (Fig. 3B) . Conversely, some T4 clusters were inversely correlated with Mo_180 and Mo_243, in particular clusters T4_6, T4_20, and T4_34, all three corresponding to naïve cells (CD45RA high CD45RO low CCR7 high ), and T4_59 expressing a Th2 phenotype (CCR4 high ). We then compared the abundance of these 29 lymphoid clusters correlated with Mo180 and Mo243 and highlighted the 22 differentially represented lymphoid clusters between the three groups of patients (P < 0.05) ( Fig. 3C and Fig. S2 ). Only 7 clusters of CD4 T cells, and 2 clusters of CD8 T cells were at lower abundance in COVID-19 pos ARDS pos patients compared to COVID-19 neg ARDS pos patients. As previously discussed, T4_6, T4_20, and T4_34 corresponded to naïve cells, whereas within the effector memory cells, T4_7 and T4_45 were CD127 low , T4_24, T8_99, and T8_113 were CD127 high , and T4_59 was CCR4 high . Conversely, 13 clusters were enriched in COVID-19 pos ARDS pos compared to COVID-19 neg ARDS pos including: i) CTLA4 high PD1 high effector memory activated CD4 Tcells (T4_106); ii) Tbet high Th1-like CD8 effector phenotype (T8_146, T8_147, and T8_161); iii) cytotoxic mature CD16 pos CD56 low CD7 pos Tbet pos CD127 neg NK cells (NK_209, NK_241, NK_242, and NK_244) with in particular proliferating Ki-67 high NK cells (NK_241); and iv) proliferating plasmablasts (plasmo_183) and mature plasma cells (plasmo_198) (Fig. 3B and Fig. 3C ). Of note, no cluster was differentially expressed between COVID-19 pos ARDS pos and COVID-19 pos ARDS neg groups ( Fig. 3C and Fig. S2 ). Then, to explore the whole immune profile and define relationship with groups of patients, we performed correspondence analysis (CA) using, as a variable, the abundance of the myeloid (n = 4) and the lymphoid (n = 22) clusters differentially expressed between groups of patients (Fig. 3D) . CA was J o u r n a l P r e -p r o o f developed to analyze frequency tables and visualize similarities between patients and cooccurrence of cell subsets. 41 The first and second dimension of the correspondence analysis explained 80.5 % and 13.5 % of the difference, respectively (Fig. 3D ). The top-ten cell populations accounting for the difference between COVID pos and COVID neg patients were Mo243, Mo180, T8_146, NK_244, and T8_161 being increased and Mo181, T4_6, Mo11, T8_99, and T4_45 being decreased in COVID pos . Altogether, these subsets corresponded to an increase in inflammatory monocytes (CD169 high CD64 high ), Tbet high Th1-like CD8 T cells, and mature NK cells and a decrease in naïve T4 cells and effector memory T4 and T8 cells.

Interestingly, only the first dimension of the correspondence analysis segregated COVID-19 pos ARDS pos from COVID-19 neg ARDS pos (P < 0.001) and no statistical differences was found between COVID-19 pos ARDS pos and COVID-19 pos ARDS neg (Fig. 3D ).

We performed mass cytometry analysis for 21 patients at day 7 of hospitalization, including 7 COVID-19 neg ARDS pos , 8 COVID-19 pos ARDS pos , and 6 COVID pos ARDS neg patients, in order to follow up the kinetic of PBMC phenotypic alterations. The 42 samples (21 at day 0 and 21 at day 7) were parsed by correspondence analysis using, as a variable, the abundance of myeloid and lymphoid clusters (Fig. 4A ). The first and second dimensions of the correspondence analysis explained 85.1 % and 9 % of the differences acquired between D0 and D7. The first dimension captured the difference between D0 and D7 only for COVID-19 pos ARDS pos (P < 0.01) (Fig. 4A) .

Because of the limited number of samples, only a trend was observed for COVID pos ARDS neg (P = 0.062). The top-five enriched populations accounting for the differences between D0 and D7 for COVID-19 pos ARDS pos patients were Mo11, Mo181, T8_113, T4_34, and NK_197, corresponding J o u r n a l P r e -p r o o f to an enrichment in non-classical monocytes (CD14 low CD16 high CD64 low CD36 low S100A9 high ), in M-MDSC-like (HLA-DR low S100A9 high ), in effector memory CD127 high T8 cells, in T4 naïve cells, and in Ki-67 high proliferating NK cells. These 5 cell subsets were integrated in an immune score combining their fold change between D0 and D7. To define the relevance of this immune score in discriminating COVID-19 patients with unfavorable prognosis, we built a clinical score as the sum of events occurring during ICU stay (thromboembolic, ICU-acquired infection, septic shock, renal failure, and deaths) ( Table 1) . Interestingly, both the clinical and the immune scores were found correlated in severe COVID-19 patients, irrespectively of their ARDS status (Spearman R = 0.71; P = 0.006) (Fig. 4B ). Finally, we analyzed changes between D0 and D7 of genes involved in IFN pathway. We found and upregulation of IFNAR1 and IFNAR2 during time in COVID pos ARDS pos (Fig. S5A) . Conversely, evolution of IFN type I target genes (ISG15, IFI27, IFI44L, RSAD2, and IFIT1) revealed a specific downregulation in COVID pos ARDS pos samples. Interestingly, both IFNAR score and type I IFN score, obtained by combining the expression of IFN receptors and targets, respectively, presented a trend of correlation with the immune score (Fig. S5B) , and the type I IFN score was significantly correlated with the CD169 expression ( Fig. S5C ).

Immune response to COVID-19 infection has been recently intensively studied at both transcriptomic and proteomic levels. However, most studies focused on either the lymphoid 19, 22, 24 or the myeloid compartments, 12, 21, 23 and only few performed a wide analysis of the circulating immune landscape, 13, 16, 25, 42, 43 thus precluding the definition of complex patterns of immune parameter alterations associated with COVID-19 severity or physiopathology. Moreover, these studies were designed to identify differences in immune cell subsets frequencies between J o u r n a l P r e -p r o o f COVID-19 patients and healthy donors, and eventually correlated with the severity of the disease, but did not include severe non-COVID-19 patients as controls, although critically ill patients were previously largely demonstrated to display immune reprogramming. 44 ARDS is a major adverse event occurring during ICU stay, leading to an overall mortality rate of 40 % to 60 %.

Whether COVID-19 associated ARDS is clinically and biologically similar to other causes of ARDS remains controversial. 45, 46 To address this point, we characterized for the first time, by mass cytometry, the immune landscape in COVID-19-associated ARDS compared to other causes of ARDS. We demonstrated that an increase of CD169 pos monocytes, correlated with specific changes of T, plasma, and NK cell subsets, defines COVID-19-associated ARDS and is not found in bacteria-associated ARDS, suggesting a COVID-19 specific immune reprogramming.

The amplification of CD169 pos circulating monocytes has already been highlighted in the context of COVID-19, 15, 23, 38, 47 and is reminiscent of other inflammatory conditions found in viral infections, such as with Human Immunodeficiency Virus or Epstein-Barr Virus, in which the CD169 sialoadhesin is induced in an IFN-dependent manner on the surface of circulating monocytes. 48, 49 Consistent with the inflammatory response, we showed that the accumulation of CD169 pos monocytes in COVID-19 pos patients is positively correlated with an increase of plasmablasts and mature plasma cells, Th1-like CD8 effector T cells, cytotoxic mature NK cells, and activated CD4 effector memory T cells displaying a CTLA4 high PD1 high phenotype. CD169 pos activated monocytes were detected in mild disease, 23 and were proposed to rise rapidly and transiently in patients with COVID-19, in association with a high expression of IFNγ and CCL8. 15 This could be due to the transient nature of this monocytic population, either losing CD169, being short-lived, or being recruited into tissues as CD169 pos macrophages, as suggested by the high expression of CCR2 on Mo243 and Mo180, the two monocyte subsets identified here J o u r n a l P r e -p r o o f in COVID-19 patients, and the local inflammation and lung tissue destruction mediated by monocyte-derived macrophages in severe cases of SARS-CoV2 infections. 50, 51 Interestingly, we also found an upregulation of cytoplasmic S100A9 in monocyte subsets specifically amplified in COVID-19 patients irrespectively of their ARDS status. These data suggest that, in the early stage of the disease, monocytes could contribute to the burst of circulating calprotectin (S100A8/S100A9), recently proposed to contribute to the secondary cytokine release syndrome described in severe COVID-19 and attributed to neutrophils. 21 Despite phenotypic alterations, our data revealed a specific alteration of the response to type I IFN in COVID-19 pos versus COVD-19 neg ARDS patients after short stay in ICU, with an upregulation of IFN receptors without induction of IFN target genes. These results are reminiscent of the demonstration that deficiency of type I IFN pathway is associated with poor outcome in COVID-19 patients. 52, 53 Whereas a seroconversion score was recently associated with huge modifications immune parameters reflecting B, T, and NK cell function in non-ICU COVID patients, 54 our ICU patients clearly stand at a later stage of the disease, with 22 out of 29 already carrying neutralizing antibodies at D0. It is thus highly unlikely that the differential evolution of monocytic markers identified between D0 and D7 in our study could be attributable to seroconversion.

Within severe COVID-19 patients, we detected no significant differences between ARDS pos and ARDS neg immune profiles, indicating a specificity of the phenotype induced by SARS-CoV2 infection, irrespectively of the respiratory complications. While most published studies showed differences between mild and severe COVID-19 diseases, some of their conclusions might be obscured by the fact that ARDS by itself, mechanical ventilation, and/or nonspecific treatments might impact immune parameters. 55 A strength of our study comparing two groups of severe COVID-19 patients with or without ARDS is to highlight features directly related to the viral infection rather than to its respiratory complications or their treatment. Importantly, our cohort J o u r n a l P r e -p r o o f was homogeneous regarding treatment with in particular no immunosuppressive therapy at the time of sampling.

The small size of our cohort did not allow us to pinpoint a mortality prognostic factor based on our phenotypic data. However, we identified a specific immune pattern associated with the occurrence of the major adverse clinical events (thrombosis, nosocomial infection, septic shock, acute renal failure, and death) described in COVID-19 and combined as a clinical score. In 

Besides the low number of included patients, our study has some limitations. By focusing on severe patients with and without ARDS, we cannot make conclusions about phenotypic changes in mild and moderate diseases. The analysis would also benefit from comparison with other virusassociated ARDS. We thus analyzed a published dataset of flu-like illness and COVID patients, analyzed by mass cytometry. 21 Interestingly, by using CellCnn, we were able to define a filter that accurately discriminate flu-like illness from COVID samples, suggesting immune differences between both diseases (Fig. S4) . Moreover, since the mass cytometry was conducted on PBMCs, J o u r n a l P r e -p r o o f we lack information on the neutrophil lineage, which appears affected in COVID-19 disease. 21 It would also be interesting to link these data with in situ data from lung tissue samples and 

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Mikael Roussel (mikael.roussel@chu-rennes.fr)

The study did not generate new unique reagents. 

This study was performed in the infectious diseases department and intensive care unit (ICU) at

Rennes University Hospital. The study design was approved by our ethic committee (CHU Rennes, n°35RC20_9795_HARMONICOV, ClinicalTrials.gov Identifier: NCT04373200) and

informed consent was obtained from patients in accordance with the Declaration of Helsinki.

Patients with malignancy, HIV-infected patients, and patients with preexisting immune disorders or receiving immunosuppressive agents were excluded. The presence of SARS-CoV-2 in respiratory specimens (nasal and pharyngeal swabs or sputum) was detected by real-time reverse transcription polymerase chain reaction (RT-PCR) methods (TaqPath COVID-19, ThermoFisher). samples were drawn at D0 and D7. PBMC were isolated from whole blood using ficoll before cryopreservation. All patients provided written informed consent. The following data were recorded: gender, age, preexisting chronic kidney disease and acute kidney failure during the ICU stay, 61 preexisting chronic heart failure, 62 Body Mass Index (BMI), SAPS II at admission, 63 duration of mechanical ventilation, length of hospital stay, and outcome (alive or dead) on day 7, day 30 and day 90. The occurrence of nosocomial infection, defined following CDC criteria as previously described, 64 was also recorded during hospital stay. For each patient, a clinical score was built to summarize the occurrence of adverse clinical events frequently encountered during hospitalization. 64, 65 Each of the following events: thromboembolic events, nosocomial infection, septic shock, acute renal failure, and death counting as one point, the score varies from 0 (no adverse events) to 5. Patients' characteristics for cohort 1 are reported in Table 1 and Table S1 .

Cohort 2: Same inclusion criteria were applied to cohort 2. Only patients at D0 were included.

Patients' characteristics for cohort 1 are reported in Table S1 and Table S2 .

PBMC from patients were thawed. Briefly, cells were stained 5 minutes in RPMI supplemented Table S3 and in Key Resources Table. After intracellular staining, cells were washed twice before staining in DNA intercalator solution (2.5% Paraformaldehyde, 1:3200 Cell-ID™ Intercalator-Ir (Fluidigm, San Francisco, CA) in PBS). Samples were cryopreserved at -80°C until acquisition on Helios™ System (Fluidigm, San Francisco, CA).

Purified antibodies for mass cytometry were obtained in carrier/protein-free buffer and then coupled to lanthanide metals using the MaxPar antibody conjugation kit (Fluidigm Inc.)

according to manufacturer's recommendations. Following the protein concentration determination by measurement of absorbance at 280 nm and titration on positive controls, the metal-labeled antibodies were diluted in Candor PBS Antibody Stabilization solution (Candor Bioscience, Germany) for long-term storage at 4°C. Antibodies used are listed in Table S3 and Key Resources Table. Quantitative 

Identification of a Covid-19-specific cell-identity signature was carried out using the CellCnn algorithm, 35 Spearman test. * P < 0.05, ** P < 0.01, *** < 0.001, and **** P < 0.0001. Hierarchical clustering of the patients was performed using euclidean distance and complete clustering. Correspondence analysis was performed using the package factoshiny using as variable the abundance in cell subsets for each patient.

Supplementary Materials: Figure S1 . Description of the 2 cohorts of patients, CyTOF experimental design and data analysis pipeline. Related to Table 1 and Figures 1 and 2 . 

Factors associated with COVID-19-related death using OpenSAFELY

Clinical Characteristics of Coronavirus Disease 2019 in China

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China

High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study

COVID-19 and the human innate immune system

Clinical and immunologic features in severe and moderate Coronavirus Disease

Severe COVID-19 is associated with deep and sustained multifaceted cellular immunosuppression

Early High-Titer Plasma Therapy to Prevent Severe Covid-19 in Older Adults

COVID-19: a novel coronavirus and a novel challenge for critical care

Corticosteroid use in COVID-19 patients: a systematic review and meta-analysis on clinical outcomes

The effect of corticosteroids on mortality of patients with influenza pneumonia: a systematic review and meta-analysis

Expansion of myeloidderived suppressor cells in patients with severe coronavirus disease (COVID-19)

Systems biological assessment of immunity to mild versus severe COVID-19 infection in humans

T cell responses in patients with COVID-19

A distinct innate immune signature marks progression from mild to severe COVID-19

Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients

Longitudinal analyses reveal immunological misfiring in severe COVID-19

Longitudinal immune profiling reveals key myeloid signatures associated with COVID-19

Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications

Large-scale single-cell analysis reveals critical immune characteristics of COVID-19 patients

Severe COVID-19 Is Marked by a Dysregulated Myeloid Cell Compartment

Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19

Elevated Calprotectin and Abnormal Myeloid Cell Subsets Discriminate Severe from Mild COVID-19

Immunological and inflammatory profiles in mild and severe cases of COVID-19

A singlecell atlas of the peripheral immune response in patients with severe COVID-19

Complex Immune Dysregulation in COVID-19 Patients with Severe Respiratory Failure

Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages

A Dynamic Immune Response Shapes COVID-19 Progression

SARS-CoV-2-Induced ARDS Associates with MDSC Expansion, Lymphocyte Dysfunction, and Arginine Shortage

Distinct inflammatory profiles distinguish COVID-19 from influenza with limited contributions from cytokine storm

Marked T cell activation, senescence, exhaustion and skewing towards TH17 in patients with COVID-19 pneumonia

Expansion of plasmablasts and loss of memory B cells in peripheral blood from COVID-19 patients with pneumonia

Immunology of COVID-19: Current State of the Science

Acute respiratory distress syndrome: the Berlin Definition

Sensitive detection of rare disease-associated cell subsets via representation learning

GM-CSF and CXCR4 define a T helper cell signature in multiple sclerosis

Highdimensional single-cell analysis predicts response to anti-PD-1 immunotherapy

Monocyte CD169 Expression as a Biomarker in the Early Diagnosis of Coronavirus Disease

CD169 and CD64 could help differentiate bacterial from CoVID-19 or other viral infections in the Emergency Department

Monocyte CD169 expression in COVID-19 patients upon intensive care unit admission

An Immune Atlas of Clear Cell Renal Cell Carcinoma

Comprehensive mapping of immune perturbations associated with severe COVID-19

A dynamic COVID-19 immune signature includes associations with poor prognosis

The immune system's role in sepsis progression, resolution, and longterm outcome

Clinical features, ventilatory management, and outcome of ARDS caused by COVID-19 are similar to other causes of ARDS

Covid-19 Does Not Lead to a "Typical" Acute Respiratory Distress Syndrome

Whole blood immunophenotyping uncovers immature neutrophil-to-VD2 T-cell ratio as an early marker for severe COVID-19

Epstein-Barr virus lytic infection promotes activation of Toll-like receptor 8 innate immune response in systemic sclerosis monocytes

Sialoadhesin expressed on IFN-induced monocytes binds HIV-1 and enhances infectivity

Association of COVID-19 inflammation with activation of the C5a-C5aR1 axis

Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19

Autoantibodies against type I IFNs in patients with life-threatening COVID-19

Inborn errors of type I IFN immunity in patients with life-threatening COVID-19

Seroconversion stages COVID19 into distinct pathophysiological states

Norepinephrine Dysregulates the Immune Response and Compromises Host Defense during Sepsis

Induction of a regulatory myeloid program in bacterial sepsis and severe COVID-19

Mitochondrial induced T cell apoptosis and aberrant myeloid metabolic programs define distinct immune cell subsets during acute and recovered SARS-CoV-2 infection

The differential immune responses to COVID-19 in peripheral and lung revealed by single-cell RNA sequencing

COVID-19 severity associates with pulmonary redistribution of CD1c+ DC and inflammatory transitional and nonclassical monocytes

COVID-19-associated acute respiratory distress syndrome: is a different approach to management warranted?

Definition and classification of chronic kidney disease: A position statement from Kidney Disease: Improving Global Outcomes (KDIGO)

ESC Guidelines for the diagnosis and treatment of acute and chronic heart failureThe Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC

A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study

Immune Dysfunction After Cardiac Surgery with Cardiopulmonary Bypass

Herpes simplex virus and cytomegalovirus reactivations among severe COVID-19 patients

We thank all donors, families, and surrogates, as well as the medical